Induced Proximity & Small Molecule Drug Development Conferences

2026 has emerged as a defining year for small molecule therapeutics, with 27 FDA approvals, including three induced proximity medicines. As clinical breakthroughs increasingly translate into regulatory success, the field is reaching a critical inflection point where scientific innovation is delivering tangible therapeutic impact at scale. Momentum is building rapidly across novel targets, emerging modalities and new disease areas, expanding the scope of what small molecules can achieve.

At this pivotal moment, we are dedicated to uniting the experts advancing small molecule and induced proximity therapeutics to share the insights, data and strategies shaping the next generation of selective, tolerable and transformative medicines.